Trade Aquestive Therapeutics, Inc. - AQST CFD

Trading Conditions

• TypeThis financial instrument is available for trading through CFDs and Knock-outs.Knock-out options available only for selected countries.Learn more about:CFDsKnock-outs:
  CFD

  

  Knock-out

  
• Spread: 0.0282
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021568 %(-$0.43)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.02157%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000654 %(-$0.01)Trade size with leverage ~ $2,000.00Money from leverage ~$1,000.00Go to platform: -0.00065%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021568 %
  (-$0.43)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000654 %
  (-$0.01)

Key Stats

• Prev. Close: 3.7109
• Open: 3.7209
• 1-Year Change: -4.31%
• Day's Range: 3.6009 - 3.7209

Trade Aquestive Therapeutics, Inc. - AQST

About Aquestive Therapeutics Inc

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing differentiated products which leverage PharmFilm. Its late-stage product pipeline focused on the treatment of central nervous system (CNS), diseases and an earlier stage pipeline including treatment of anaphylaxis. Its commercialized licensed product is Suboxone, a sublingual film formulation of buprenorphine and naloxone, for the treatment of opioid dependence. Its CNS portfolio focused on epilepsy includes, Sympazan an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut syndrome (LGS). Its portfolio also includes Suboxone a sublingual film formulation of buprenorphine and naloxone, respectively an opioid agonist and antagonist for the treatment of opioid dependence.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Aquestive Therapeutics Inc revenues increased 11% to $50.8M. Net loss increased 26% to $70.5M. Revenues reflect Ex-United States segment increase of 63% to $8M, United States segment increase of 5% to $42.9M. Higher net loss reflects Interest expense related to the sale increase from $2M to $12.4M (expense), Stock-based Compensation in R&D increase of 21% to $881K (expense).

Equity composition

Common Stock $.01 Par, Shares auth. and o/s after the offering: 100M auth., 15,029,412 issd. Insiders own approx. 1% (after the IPO). IPO: TBA. 4M shares Offered. 03/08, IPO withdrawn.